How Myomo Will Be The First Reg A+ IPO To Trade On The NYSE MKT
Webinar Overview
Myomo, Inc. is a commercial stage medical robotics company seeking to become the first company to launch a Regulation A+ IPO with listing on the New York Stock Exchange MKT (NYSE MKT). Myomo develops and markets the MyoPro® product line of lightweight, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals who have suffered a stroke, spinal cord, or nerve injury, or other neuromuscular disability so that they can return to work, live independently and reduce their cost of care.
Join Myomo CEO, Paul Gudonis, for their Roadshow Investor Webinar April 12, 2017 at 2:00 p.m. EST.
The discussion will explore topics such as:
- The company’s roadmap to the New York Stock Exchange MKT (NYSE MKT)
- What Regulation A+ means for investors
- What you need to know about the company’s non-invasive technology
- How the company plans to grow
Sign up now to take part in the live discussion.
[author]Myomo Inc.’s offering statement for its initial public offering under Regulation A has been qualified by the Securities and Exchange Commission. The securities offered by Myomo Inc. are highly speculative. Investing in shares of Myomo Inc. involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. To obtain a copy of the Offering Circular, go to Myomo Form 1-A at https://goo.gl/z7npq1 [/author]
